Atrion Co. (ATRI) Given Consensus Recommendation of “Strong Sell” by Analysts

Shares of Atrion Co. (NASDAQ:ATRI) have earned a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.

Zacks has also given Atrion an industry rank of 79 out of 265 based on the ratings given to related companies.

Separately, BidaskClub lowered Atrion from a “hold” rating to a “sell” rating in a research note on Friday, December 29th.

Shares of Atrion (ATRI) opened at $594.60 on Monday. Atrion has a one year low of $459.05 and a one year high of $694.00. The stock has a market capitalization of $1,106.20, a P/E ratio of 32.94 and a beta of 0.85.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share (EPS) for the quarter. Atrion had a return on equity of 18.34% and a net margin of 22.98%. The firm had revenue of $37.90 million during the quarter.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc lifted its stake in shares of Atrion by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock worth $216,000 after acquiring an additional 14 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Atrion by 25.7% during the 4th quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock worth $376,000 after acquiring an additional 122 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Atrion by 10.2% during the 2nd quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock worth $486,000 after acquiring an additional 70 shares during the last quarter. Advisor Group Inc. raised its position in Atrion by 5,826.7% during the 3rd quarter. Advisor Group Inc. now owns 889 shares of the medical instruments supplier’s stock valued at $598,000 after purchasing an additional 874 shares in the last quarter. Finally, Susquehanna International Group LLP raised its position in Atrion by 187.6% during the 3rd quarter. Susquehanna International Group LLP now owns 1,369 shares of the medical instruments supplier’s stock valued at $920,000 after purchasing an additional 893 shares in the last quarter. 59.06% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/29/atrion-co-atri-given-consensus-recommendation-of-strong-sell-by-analysts.html.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Get a free copy of the Zacks research report on Atrion (ATRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply